Related references
Note: Only part of the references are listed.IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Remco J. Molenaar et al.
CLINICAL CANCER RESEARCH (2018)
Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis
Daniel R. Wahl et al.
CANCER RESEARCH (2017)
Venetoclax for the treatment of chronic lymphocytic leukemia
Massimo Gentile et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Laurence M. Gagne et al.
TRENDS IN CELL BIOLOGY (2017)
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Georg Karpel-Massler et al.
NATURE COMMUNICATIONS (2017)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma
Mohammed Khurshed et al.
ONCOTARGET (2017)
Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours
Remco J. Molenaar et al.
BMJ OPEN (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation
Andrea E. Calvert et al.
CELL REPORTS (2017)
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression
Luisa Cimmino et al.
CELL (2017)
Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Qingyu Xu et al.
CLINICAL CANCER RESEARCH (2017)
Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells
Mahsa Zarei et al.
CANCER RESEARCH (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael D. Amatangelo et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity
Kensuke Tateishi et al.
CANCER RESEARCH (2017)
Oncometabolites D- and L-2-Hydroxyglutarate Inhibit the AIkB Family DNA Repair Enzymes under Physiological Conditions
Fangyi Chen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
Helena Boutzen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Supriya K. Saha et al.
CANCER DISCOVERY (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Metabolic control of epigenetics in cancer
Adam Kinnaird et al.
NATURE REVIEWS CANCER (2016)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Remco J. Molenaar et al.
CANCER RESEARCH (2015)
FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression
Paraskevi Charitou et al.
EMBO REPORTS (2015)
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
R. J. Molenaar et al.
LEUKEMIA (2015)
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Ujunwa C. Okoye-Okafor et al.
NATURE CHEMICAL BIOLOGY (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
Lipika Goyal et al.
ONCOLOGIST (2015)
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
Elisabet Cuyas et al.
ONCOTARGET (2015)
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
Pu Wang et al.
CELL REPORTS (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Jinlong Shi et al.
TUMOR BIOLOGY (2015)
Autophagy and oxidative stress in gliomas with IDH1 mutations
Misty R. Gilbert et al.
ACTA NEUROPATHOLOGICA (2014)
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Andrew X. Zhu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo
Ju-Bo Wang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
Alexandra R. Grassian et al.
CANCER RESEARCH (2014)
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
Ashkan Emadi et al.
EXPERIMENTAL HEMATOLOGY (2014)
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
Anh N. Tran et al.
NEURO-ONCOLOGY (2014)
Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas
Sanne A. M. van Lith et al.
NEURO-ONCOLOGY (2014)
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
Remco J. Molenaar et al.
NEURO-ONCOLOGY (2014)
An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation
Jinlong Shi et al.
NEUROLOGICAL SCIENCES (2014)
A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Adnan Elhammali et al.
CANCER DISCOVERY (2014)
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death
Isabelle Vanessa Mohrenz et al.
APOPTOSIS (2013)
Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity
Sung Youl Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Anuhar Chaturvedi et al.
BLOOD (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
Kdm4b Histone Demethylase Is a DNA Damage Response Protein and Confers a Survival Advantage following γ-Irradiation
Leah C. Young et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
Martje Toenjes et al.
NATURE MEDICINE (2013)
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
Sichen Li et al.
NEURO-ONCOLOGY (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG
Anna C. Navis et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2013)
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
Qi SongTao et al.
CANCER SCIENCE (2012)
RNF8-and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites
Frederick A. Mallette et al.
EMBO JOURNAL (2012)
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function
Masato Sasaki et al.
GENES & DEVELOPMENT (2012)
Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance
Yuejun Fu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
Yoshiko Okita et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Reductive carboxylation supports growth in tumour cells with defective mitochondria
Andrew R. Mullen et al.
NATURE (2012)
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Christian M. Metallo et al.
NATURE (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Peppi Koivunen et al.
NATURE (2012)
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Masato Sasaki et al.
NATURE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
Christian Hartmann et al.
CLINICAL CANCER RESEARCH (2011)
Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1R132 Mutation Effects in Human Glioblastoma
Nadia A. Atai et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
Twinkal C. Pansuriya et al.
NATURE GENETICS (2011)
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability
David R. Wise et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
Fonnet E. Bleeker et al.
ACTA NEUROPATHOLOGICA (2010)
Thioredoxin and thioredoxin reductase: Current research with special reference to human disease
Arne Holmgren et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Meghan J. Seltzer et al.
CANCER RESEARCH (2010)
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
C. Houillier et al.
NEUROLOGY (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Oxalomalate regulates ionizing radiation-induced apoptosis in mice
Jin Hyup Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology
DR Spitz et al.
CANCER AND METASTASIS REVIEWS (2004)
D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats
A Latini et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Reduced nicotinamide adenine dinucleotide phosphate and the higher incidence of pollution-induced liver cancer in female flounder
A Koehler et al.
ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY (2003)
NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in D-2-hydroxyglutaric aciduria
S Kölker et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Share Paper
